QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2034

Conditions

Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Interventions

DRUG

Iparomlimab and Tuvonralimab (QL1706)Injection

PD-1/CTLA-4

DRUG

Paclitaxel

Chemotherapy

DRUG

Cisplatin

Chemotherapy

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY